OverviewSuggest Edit

Agenus is a clinical-stage immuno-oncology company which focuses on the discovery and development of therapies that engage the body's immune system for patients suffering with cancer. The Company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies, SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies, and phage display technologies. It is also developing checkpoint modulating antibody candidates. In addition, the Company develops cancer and tumor vaccine programs and a saponin-based vaccine adjuvant for the treatment of malaria and shingles.

TypePublic
Founded1994
HQLexington, US
Websiteagenusbio.com
Employee Ratings3.3

Latest Updates

Employees (est.) (Feb 2020)328(+12%)
Job Openings28
Revenue (FY, 2019)$150 M(+308%)
Share Price (Nov 2020)$3.9 (+2%)
Cybersecurity ratingDMore

Key People/Management at Agenus

Garo Armen

Garo Armen

Chairman and CEO
Garo H. Armen

Garo H. Armen

Chairman and CEO
Jennifer Buell

Jennifer Buell

President and Chief Operating Officer
Anna Wijatyk

Anna Wijatyk

Vice President of Clinical Development
Julie Desander

Julie Desander

Vice President, Business Development and Alliance Management
Sunil Gupta

Sunil Gupta

Vice President of Regulatory & Pharmacovigilance
Show more

Agenus Office Locations

Agenus has offices in Lexington, Berkeley, New York and Cambridge
Lexington, US (HQ)
3 Forbes Rd
Berkeley, US
793 Heinz Ave
New York, US
149 5th Ave #500
Cambridge, GB
315 Science Park Milton Road
Show all (4)

Agenus Financials and Metrics

Agenus Revenue

Agenus's revenue was reported to be $150.05 m in FY, 2019
USD

Revenue (Q2, 2020)

26.9m

Gross profit (Q2, 2020)

26.3m

Gross profit margin (Q2, 2020), %

97.6%

Net income (Q2, 2020)

(48.2m)

EBIT (Q2, 2020)

(33.3m)

Market capitalization (17-Nov-2020)

749.2m

Closing stock price (17-Nov-2020)

3.9

Cash (30-Jun-2020)

79.2m

EV

707.3m
Agenus's current market capitalization is $749.2 m.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

16.0m3.0m7.0m24.8m22.6m42.9m36.8m150.0m

Revenue growth, %

129%256%(9%)

Cost of goods sold

672.0k536.1k

Gross profit

15.3m2.5m7.0m
Quarterly
USDQ2, 2011Q3, 2011Q4, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

786.4k653.7k2.8m13.4m626.8k868.8k1.1m807.4k736.0k720.9k3.1m1.6m4.0m6.4m6.8m6.0m6.6m4.4m27.0m4.2m3.4m1.6m15.9m12.8m79.9m15.7m19.9m15.1m26.9m

Cost of goods sold

23.7k128.5k217.2k272.8k176.7k80.1k634.0k

Gross profit

786.4k653.7k2.8m13.4m498.3k651.6k836.5k630.7k655.9k720.9k3.1m1.6m26.3m

Gross profit Margin, %

100%100%100%100%80%75%75%78%89%100%100%100%98%
USDQ2, 2011

Financial Leverage

-1.3 x
Show all financial metrics

Agenus Cybersecurity Score

Cybersecurity ratingPremium dataset

D

66/100

SecurityScorecard logo

Agenus Online and Social Media Presence

Embed Graph

Agenus News and Updates

Agenus and Dr. Steven O’Day to Participate in Panels at the Virtual SITC 2020 Immuno-Oncology Event Hosted by B. Riley

LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Steven O’…

Agenus Presents Additional Clinical Responses and Novel Biomarker Data at SITC2020

LEXINGTON, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) --  Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced presentations on …

Agenus R&D Update & Third Quarter Financial Report

LEXINGTON, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate and optimize immune response to cancers and infections, today provided a corp…

Agenus to Report Third Quarter Earnings

Conference Call and Webcast on Thursday, October 29, 2020 from 8:30 – 9:30 am Conference Call and Webcast on Thursday, October 29, 2020 from 8:30 – 9:30 am

Agenus to Present on Seven Novel Programs at SITC 2020

LEXINGTON, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that seven abstracts…

Agenus Initiates Rolling BLA Submission of Balstilimab for Recurrent/Metastatic Cervical Cancer

LEXINGTON, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, announced the initiation of the rol…
Show more

Agenus Blogs

Agenus to Participate in Fireside Chat at the Jefferies 2020 Virtual London Healthcare Conference

Agenus to Participate in Fireside Chat at the Jefferies 2020 Virtual London Healthcare Conference Content Import Mon, 11/16/2020 - 19:04 Agenus to Participate in Fireside Chat at the Jefferies 2020 Virtual London Healthcare Conference November 16, 2020 This r…

Agenus and Dr. Steven O’Day to Participate in Webcast Hosted by William Blair on AGEN1181 and SITC Data

LEXINGTON, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) --  Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr.

An Agenus-discovered first-in-class ILT4 antibody, MK-4830, enters Phase 2

$10M milestone payment from Merck triggered Agenus is eligible for up to an additional $85 million in milestones plus royalties on sales LEXINGTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies,

Dr. Steven O’Day Named Agenus Chief Medical Officer

Dr. Steven O’Day Named Agenus Chief Medical Officer Content Import Thu, 11/05/2020 - 08:01 Dr. Steven O’Day Named Agenus Chief Medical Officer November 5, 2020 This release is a backfill from a News Wire General Release …

Agenus Doses First COVID-19 Patient with iNKT Cell Therapy

Agenus Doses First COVID-19 Patient with iNKT Cell Therapy Content Import Mon, 11/02/2020 - 08:45 Agenus Doses First COVID-19 Patient with iNKT Cell Therapy November 2, 2020 This release is a backfill from a News Wire General Release …
Show more

Agenus Frequently Asked Questions

  • When was Agenus founded?

    Agenus was founded in 1994.

  • Who are Agenus key executives?

    Agenus's key executives are Garo Armen, Garo H. Armen and Jennifer Buell.

  • How many employees does Agenus have?

    Agenus has 328 employees.

  • What is Agenus revenue?

    Latest Agenus annual revenue is $150 m.

  • What is Agenus revenue per employee?

    Latest Agenus revenue per employee is $457.5 k.

  • Who are Agenus competitors?

    Competitors of Agenus include LogicBio Therapeutics, ABL Bio and Shanghai Henlius Biotech.

  • Where is Agenus headquarters?

    Agenus headquarters is located at 3 Forbes Rd, Lexington.

  • Where are Agenus offices?

    Agenus has offices in Lexington, Berkeley, New York and Cambridge.

  • How many offices does Agenus have?

    Agenus has 4 offices.